Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 1
2002 2
2005 2
2006 1
2010 1
2011 1
2013 1
2014 2
2016 2
2017 4
2018 3
2019 2
2020 5
2021 3
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
The difference in response rate based on SALT score 20 or less between the placebo and the ritlecitinib 200 mg + 50 mg group was 29.1% (95% CI 21.2-37.9; p<0.0001), 20.8% (13.7-29.2; p<0.0001) for the 200 mg + 30 mg group, 21.9% (14.7-30.2; p<0.0001) …
The difference in response rate based on SALT score 20 or less between the placebo and the ritlecitinib 200 mg + 50 mg group was 29.1% (95% …
A short review of experimental peritoneal sclerosis: from mice to men.
Gotloib L, Wajsbrot V, Shostak A. Gotloib L, et al. Int J Artif Organs. 2005 Feb;28(2):97-104. doi: 10.1177/039139880502800204. Int J Artif Organs. 2005. PMID: 15770597 Review.
Acute exfoliation induced by deoxycholate resulted in a depopulated monolayer coincident with immediate alteration of the peritoneal permeability, evidenced by increased urea D/P ratio, higher glucose absorption rate, elevated albumin losses in the effluent and significant …
Acute exfoliation induced by deoxycholate resulted in a depopulated monolayer coincident with immediate alteration of the peritoneal permeab …
Retraction: Tilapia lake virus disease: Phylogenetic analysis reveals that two distinct clades are circulating in Israel simultaneously.
[No authors listed] [No authors listed] Transbound Emerg Dis. 2020 Sep;67(5):2266. doi: 10.1111/tbed.13694. Epub 2020 Jul 13. Transbound Emerg Dis. 2020. PMID: 32657541
Reference Skornik, R., Eyngor, M., Behar, A., Markovich, M.P., Wajsbrot, N., Klement, E., & Davidovich, N. (2020). Tilapia lake virus disease: Phylogenetic analysis reveals that two distinct clades are circulating in Israel simultaneously. ...
Reference Skornik, R., Eyngor, M., Behar, A., Markovich, M.P., Wajsbrot, N., Klement, E., & Davidovich, N. (2020). Tilapia …
Pharmacological treatment profiles in the FACE-BD cohort: Treatment description and complete data for bipolar subtypes.
Brodeur S, Terrisse H, Pouchon A, Godin O, Aouizerate B, Aubin V, Bellivier F, Belzeaux R, Bougerol T, Courtet P, Dubertret C, Gard S, Haffen E, Henry C, Leboyer M, Olié E, Roux P, Samalin L, Schwan R; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators; Etain B, Bosson JL, Polosan M. Brodeur S, et al. Data Brief. 2021 Mar 25;36:107004. doi: 10.1016/j.dib.2021.107004. eCollection 2021 Jun. Data Brief. 2021. PMID: 33855141 Free PMC article.
Temporal trends of tilapia lake virus disease in Israel, 2017-2018.
Skornik R, Behar A, Eyngor M, Perry Markovich M, Wajsbrot N, Klement E, Davidovich N. Skornik R, et al. Transbound Emerg Dis. 2021 Nov;68(6):3025-3033. doi: 10.1111/tbed.13955. Epub 2020 Dec 30. Transbound Emerg Dis. 2021. PMID: 33314697
Mann-Whitney U test showed differences in the distribution of survival rates between Israeli sequences (from 2011, 2017 and 2018) of clade A (p = 0.004) and Israeli sequences (from 2018 solely) of sub-clade IL-2018. The average survival rates of clade A and sub-clade IL-20 …
Mann-Whitney U test showed differences in the distribution of survival rates between Israeli sequences (from 2011, 2017 and 2018) of clade A …
Pharmacological treatment profiles in the FACE-BD cohort: An unsupervised machine learning study, applied to a nationwide bipolar cohort✰.
Brodeur S, Terrisse H, Pouchon A, Godin O, Aouizerate B, Aubin V, Bellivier F, Belzeaux R, Bougerol T, Courtet P, Dubertret C, Gard S, Haffen E, Henry C, Leboyer M, Olié E, Roux P, Samalin L, Schwan R, Etain B, Bosson JL, Polosan M. Brodeur S, et al. J Affect Disord. 2021 May 1;286:309-319. doi: 10.1016/j.jad.2021.02.036. Epub 2021 Feb 13. J Affect Disord. 2021. PMID: 33770539
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.
Katzman MA, Wang X, Wajsbrot DB, Boucher M. Katzman MA, et al. J Psychopharmacol. 2020 Mar;34(3):280-292. doi: 10.1177/0269881119896066. Epub 2020 Jan 8. J Psychopharmacol. 2020. PMID: 31913085
RESULTS: Desvenlafaxine 50 or 100 mg was associated with significant improvement from baseline compared to placebo for all symptom clusters (p<0.001), except a sleep cluster for desvenlafaxine 100 mg. For all symptom clusters, early improvement was significantly associa …
RESULTS: Desvenlafaxine 50 or 100 mg was associated with significant improvement from baseline compared to placebo for all symptom clusters …
Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease.
Wajsbrot NB, Leite NC, Franca PHC, Cardoso CRL, Salles GF, Villela-Nogueira CA. Wajsbrot NB, et al. Dig Dis Sci. 2024 Feb;69(2):634-642. doi: 10.1007/s10620-023-08214-7. Epub 2023 Dec 19. Dig Dis Sci. 2024. PMID: 38112841
Parental history of T2D was associated with fibrosis F2 (OR 8.89, CI 95% 1.09-72.01, p = 0.041) after adjustment for age, gender, metabolic traits and SNPs. PNPLA3 GG genotype was independently associated with steatosis S1 (OR 8.15, CI 95% 1.93-34.38, p = 0.004) and …
Parental history of T2D was associated with fibrosis F2 (OR 8.89, CI 95% 1.09-72.01, p = 0.041) after adjustment for age, gender, met …
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.
Lyndon GJ, Prieto R, Wajsbrot DB, Allgulander C, Bandelow B. Lyndon GJ, et al. Int Clin Psychopharmacol. 2019 May;34(3):110-118. doi: 10.1097/YIC.0000000000000256. Int Clin Psychopharmacol. 2019. PMID: 30870236 Free PMC article. Clinical Trial.

Change from baseline in Montgomery-Asberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant

…
Change from baseline in Montgomery-Asberg Depression Rating Scale total score and response and remission rates was significantly greater for …
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB. Weihs KL, et al. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):36-46. doi: 10.1089/cap.2017.0100. Epub 2017 Nov 30. J Child Adolesc Psychopharmacol. 2018. PMID: 29189044 Free PMC article. Clinical Trial.
Week 8 CGI-I response rates were significantly greater for fluoxetine (78.2%; p = 0.017) than for placebo (62.6%); desvenlafaxine (68.7%) did not differ from placebo. ...
Week 8 CGI-I response rates were significantly greater for fluoxetine (78.2%; p = 0.017) than for placebo (62.6%); desvenlafaxine (68 …
29 results